Abstract
Objectives
Young patients account for about half of ST-segment elevation myocardial infarction (STEMI) patients and display a unique risk profile compared with old patients. Whether these differences are related to disparities in ventricular remodeling remains unknown. This study aimed to evaluate age-related differences in ventricular remodeling after primary percutaneous coronary intervention (PPCI) for STEMI.
Methods
In this observational study, consecutive STEMI patients between October 2019 and March 2021 who underwent serial cardiovascular magnetic resonance at index admission (3 to 7 days) and 3 months after PPCI were enrolled. Adverse remodeling was defined as ≥ 10% enlargement in left ventricular end-diastolic volume index (LVEDVi), while reverse remodeling was defined as a decrease in left ventricular end-systolic volume index (LVESVi) of more than 10%.
Results
A total of 123 patients were included and grouped into young (< 60 years, n = 71) and old (≥ 60 years, n = 52) patients. Despite generally similar baseline structural and infarct characteristics, LVESVi significantly decreased only in old patients during follow-up (p = 0.034). The incidence of adverse remodeling was higher (49.3% vs 30.8%, p = 0.039), while the incidence of reverse remodeling was lower (31.0% vs 53.8%, p = 0.011) in young compared with old patients. Younger age (< 60 years) was associated with a significantly higher risk of adverse remodeling (adjusted OR 3.51, 95% CI 1.41–8.74, p = 0.007) and lower incidence of reverse remodeling (adjusted OR 0.42, 95% CI 0.18–0.97, p = 0.046).
Conclusions
In STEMI patients undergoing PPCI, young patients are at a higher risk of adverse remodeling and less probably develop reverse remodeling than old patients. Equal or more attention should be paid to young patients with STEMI compared with their older counterparts.
Key Points
• In STEMI patients undergoing PPCI, young patients displayed unfavorable remodeling compared with old patients.
• Young patients are at a higher risk of adverse remodeling and less probably develop reverse remodeling than old patients.
• Equal or more attention should be paid to young patients compared with their older counterparts.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Young individuals account for about half of all ST-segment elevation myocardial infarction (STEMI) patients and this proportion is increasing [1]. Although the incidence of acute myocardial infarction has decreased in older populations, there are no similar declines in younger individuals [2]. This group has a unique risk profile with fewer traditional cardiovascular risk factors compared with older populations. Despite timely reperfusion along with optimal medical therapy, STEMI often leads to left ventricular (LV) systolic and/or diastolic dysfunction, followed by ventricular remodeling, which has become one of the main precursors of heart failure [3]. Advanced age is an independent predictor of heart failure and mortality after primary percutaneous coronary intervention (PPCI) for STEMI [4]. However, myocardial infarction conferred a greater relative risk of heart failure in younger compared with older patients [5].
Previous studies have revealed significant differences in cardiovascular risk profiles, the extent of coronary artery disease, pathophysiology of coronary artery occlusion, and clinical outcome in patients with STEMI between age groups [4, 6,7,8,9,10,11,12]. Yet, whether these differences are related to disparities in ventricular remodeling, which are known to influence prognosis, remains undetermined [13, 14]. Therefore, we sought to compare serial cardiac magnetic resonance (CMR) data of young (< 60 years) and old (≥ 60 years) patients with STEMI undergoing PPCI to investigate age differences in ventricular remodeling.
Methods
Study population
Patients undergoing PPCI for STEMI admitted to Beijing Anzhen Hospital, Capital Medical University were prospectively considered for enrollment between 17 October 2019 and 18 March 2021. STEMI was defined according to the current European Society of Cardiology (ESC) guidelines [15]. CMR scanning was performed at index admission (3 to 7 days) and repeated at 3 months after PPCI. The main CMR exclusion criteria included contraindications to CMR, unstable clinical condition, claustrophobia, patient refusal, and reinfarction or death at any time before follow-up CMR. Patients with incomplete CMR studies or poor image quality were also excluded. Patients were stratified by a cut-off of 60 years referring to the young and the old population according to World Health Organization (WHO) [16]. This study was approved by the ethical committee of Beijing Anzhen Hospital, Capital Medical University, and all subjects provided written informed consent.
Cardiac magnetic resonance acquisition
Index admission and follow-up CMR were conducted on a 3.0-Tesla electrocardiographically gated CMR imaging system (Ingenia CX, Philips Healthcare, or MR750W, General Electric Healthcare). The imaging protocol consisted of cine images, black blood fat-suppressed T2-weighted (T2w), and late-enhanced images (LGE) 10 min after gadolinium injection (0.2 mmol/kg; Magnevist, Bayer HealthCare Pharmaceuticals Inc. This gadolinium-based contrast agent is still in use in China) at short-axis and long axis views. All sequences were acquired in breath-hold, with a field of view of 350 × 350 mm2. The whole left and right ventricle from the mitral annulus to the apex are contained in continuous short-axis slices (8-mm slice thickness, without a gap), with 25–30 phases per cardiac cycle. Long axis planes (2-, 4-, and 3-chamber views) with 5-mm slice thickness had no spacing intersection gap.
Cine CMR was performed using steady-state free precession (SSFP) with repetition time/echo time (TR/TE), 3.2/1.6 ms; flip angle (FA) = 45°; voxel size, 2.0 × 1.6 × 8 mm3, and acceleration factor = 1.5 or 3 depending on the number of slices acquired in each breath-hold. Black blood T2w imaging was performed using multishot turbo spin echo (TSE) sequence with TR = 2 heartbeat periods, TE = 75 ms, voxel size = 1.7 × 1.7 × 8 mm3, FA = 90°, and acceleration factor = 2. The inversion time of LGE images was optimized to null normal myocardium, and the imaging parameters were as follows: repetition time/echo time, 4.1/1.6 ms; flip angle, 20°; image matrix, 256 × 130.
Cardiac magnetic resonance analyses
Evaluation of images was carried out using commercially available post-processing software (CVI42, version 5.13, Circle Cardiovascular Imaging Inc.) by observers with at least 3 years of CMR experience (R.G. and Q.G.) who were blinded to all of other details and reviewed by experienced CMR cardiologists (H.W.).
Cine imaging assessed LV function, structure (myocardial mass, left ventricular end-diastolic volume index [LVEDVi], and left ventricular end-systolic volume index [LVESVi] which were calculated as LVEDV or LVESV divided by body surface area, and LV ejection fraction [LVEF]) as well as LV strain, including global longitudinal strain (GLS), global radial strain (GRS), and global circumferential strain (GCS) derived from short-axis and 1–3 slices long-axis images (2-chamber, 3-chamber, and 4-chamber planes). The global strains were calculated as the mean of the respective 16-segment peak values on the software. T2w-STIR was performed to quantify edema (area at risk, AAR) within the territory of the culprit vessel (signal intensity > 2 SDs above the mean signal in remote skeletal muscle) and intramyocardial hemorrhage (IMH) recognized as hypo-enhanced area within the edema. Infarct size is determined as hyper-enhanced myocardium with a signal intensity > 5 SDs of remote normal myocardium. Microvascular obstruction (MVO) is defined as any hypo-enhanced area within an infraction. The extent of the infarction size, IMH, and MVO were quantified as a percentage of LV myocardial mass (%LV). Consequently, the myocardial salvage index (MSI) is calculated as the percentage of the AAR that is not infarcted on LGE images: (AAR − infarct size/AAR) × 100% [17].
Percentage change (%Δ) in LVEDVi and LVESVi was calculated as the difference between the follow-up parameters and the corresponding baseline parameters and expressed as a percentage of the baseline parameters. On the basis of recent literature, after STEMI revascularization, a %ΔLVEDVi value of ≥ 10% showed a strong correlation with clinical outcomes, suggesting this criterion as the preferred CMR-based definition for post-STEMI LV adverse remodeling [13]. On the contrary, reverse remodeling was defined as a decrease in LVESVi of more than 10% on CMR images following revascularized STEMI over a period of time [14].
Statistical analyses
The distribution of data was scrutinized using the Kolmogorov–Smirnov test and visual methods such as Q-Q plots. For normally distributed continuous variables, data are presented as mean ± SD and compared by the Student’s t-test. Skewed data are expressed as medians with interquartile range (IQR) and compared using the Wilcoxon rank sum test. Categorical variables are presented as the number of cases with corresponding percentages and compared using the chi-square test or Fisher’s exact test. Differences in the changes in CMR parameters between baseline and follow-up in groups were tested by analysis of covariance and Wilcoxon rank sum test. Adverse (≥ 10% increase in LVEDVi at follow-up) or reverse remodeling (≥ 10% decrease in LVESVi at follow-up) were compared between younger and older groups and among age quantiles by chi-square test and Mantel–Haenszel test for linear trend. To evaluate predictors of adverse or reverse remodeling, multiple logistic regression procedures were tested and adjusted by significant baseline characteristics, angiographic, and baseline CMR variables (sex, current smoking, diabetes, anterior infarct, TIMI flow 0–1 pre-PCI, LVEF, and infarct size). Odds ratios (OR) with 95% confidence intervals (CI) were computed. Then, subgroup analyses stratified by clinical status and known anti-remodeling medications were done between dichotomized age (< 60 years vs. ≥ 60 years) and reverse remodeling. A 2-sided p value of < 0.05 was deemed significant. SPSS version 26.0. (SPSS Inc) was used for all statistical analyses.
Results
Clinical and angiographic characteristics
Of 284 STEMI patients with PPCI screened, 84 patients without baseline CMR and 53 patients without follow-up CMR were excluded. Patients with poor image quality and follow-up CMR > 3 months were also excluded. Finally, a total of 123 patients (median age 57.3 years, 81% men) with serial CMR were included, in which 71 patients were young (< 60 years), and 52 patients were older (≥ 60 years) (Fig. 1). Compared to the old group, young patients were more likely to be men (90.1%) and smoker (63.4%), had higher body mass index, systolic blood pressure, and heart rate and lower peak brain natriuretic peptide levels. The prevalence of traditional risk factors including hypertension and diabetes were numerally lower in young compared with old patients. In general, there were few differences in procedures or medications at discharge (Table 1).
Index and follow-up CMR findings
The median time from admission and first CMR and follow-up CMR were 4 days and 3.5 months without significant differences between age groups. The LVEF (51.1% vs 46.5%, p = 0.03) was higher and GCS (− 13.6% vs − 12.1%, p= 0.023) was greater at baseline in young patients than in the old group, whereas LVEF and GCS were similar between groups at follow-up. LVEDVi, LVESVi, LV mass index, infarct size, AAR, MSI, and prevalence or extent of MVO or IMH at baseline and follow-up were similar in both groups (Supplemental Table S1).
Changes in CMR parameters were shown in Table 2 and Figs. 2 and 3. At follow-up, ΔLVEDVi had increased numerally more in young patients than in old patients. Meanwhile, LVESVi significantly decreased only in old patients. Correspondingly, there was an absolute increase in LVESVi of 0.5 (− 5.8, 4.7) mL/m2 in young patients compared with an absolute decrease of 4.3 (− 9.2, 4.6) mL/m2 in old patients (p = 0.034). GRS was also significantly improved among old patients (8.0% IQR, 0.3–16.8) compared with young patients (5.6% IQR, 2.3–10.2) (p = 0.029). There was no significant difference between groups in the change in LVEF, LV mass index, and change in infarct characteristics.
Association between age and LV adverse and reverse remodeling
Adverse remodeling occurred in 35 (49.3%) young patients and 16 (30.8%) old patients (p = 0.039), while reverse remodeling occurred in 22 (31.0%) young patients and 28 (53.8%) old patients (p = 0.011) (Fig. 4A). Multivariable logistic regression analyses revealed that younger age (< 60 years) was independently predictive of adverse remodeling (adjusted OR 3.51, 95% CI 1.41–8.74, p = 0.007) and related to lower incidence of reverse remodeling (adjusted OR 0.42, 95% CI 0.18–0.97, p = 0.046) (Table 3). Furthermore, represented as a continuous variable, age remained significantly associated with a lower risk of adverse remodeling (adjusted OR for 1-year increase = 0.95, 95% CI 0.91–0.99, p = 0.017) and higher incidence of reverse remodeling (adjusted OR for 1-year increase = 1.05, 95% CI 1.00–1.09, p = 0.039) (Table 3).
In addition, the incidence of adverse remodeling tended to decrease with the rising quartile levels of age (54.8%, 41.9%, 35.5%, 33.3%, p for trend = 0.075), and the rate of reverse remodeling significantly increased with the rising quartile levels of age (22.6%, 41.9%, 45.2%, 53.3%, p for trend = 0.016) (Fig. 4B). After multivariable adjustment, the probability of reverse remodeling was lower in the youngest patients (quartile 1 compared with quartile 4, adjusted OR 0.26, 95% CI 0.08–0.77, p = 0.016) (Supplemental Table S2).
In subgroup analyses stratified by baseline characteristics and known anti-remodeling medication, younger age correlated with a lower incidence of reverse remodeling in men (OR 0.42, 95% CI 0.18–0.98, p = 0.046), patients with reduced LVEF (< 50%) (OR 0.36, 95% CI 0.13–0.99, p = 0.048) or dyslipidemia (OR 0.14, 95% CI 0.02–0.94, p = 0.043). Interestingly, when triple anti-remodeling drugs (β blockers, ACEI/ARB/ARNI, and mineralocorticoid receptor antagonist [MRA]) (OR 0.40, 95% CI 0.18–0.91, p = 0.028) or sodium-glucose cotransporter 2 inhibitors (SGLT2i) (OR 0.36, 95% CI 0.16–0.81, p = 0.014) was not administered, young patients showed less reverse remodeling. This was not evident in patients taking those drugs (Supplemental Fig. 1).
Discussion
In the present study, we used serial CMR data to show the impact of age on ventricular remodeling in STEMI with PPCI. Although baseline structural parameters were similar between young and old patients, young patients displayed less improvement in LVESVi and GRS compared with old patients at follow-up. Adverse remodeling was more common in the young group, while reverse remodeling was more frequent in the old group, a similar trend was also observed when subdividing age into quantiles. Younger age was significantly associated with a higher risk of adverse remodeling and a lower incidence of reverse remodeling. Specifically, the use of anti-remodeling drugs might promote reverse remodeling in younger patients compared with older patients.
Myocardial infarction remains one of the most common causes of adverse outcomes in young individuals [2]. The way in which it affects prognosis is a complex multifactorial process known as cardiac remodeling. Two echocardiography studies have reported that adverse remodeling occurred more [6] or equally [11] often in older patients (> 70 years) than younger patients irrespective of the type of reperfusion therapy (thrombolysis or PCI). However, in the contemporary era of PPCI and intensive medical therapy, few studies compared the differences in ventricular remodeling between young and old patients. Using CMR with more accurate myocardial evaluation, there was no substantial difference in baseline infarct size, AAR, MSI and MVO (myocardial injury) between young and older patients with STEMI [4, 18]. Our findings are consistent with those data. Myocardial strain, the assessment of cardiac deformation and function, is more sensitive than other parameters to identify subtle LV dysfunction resulting in adverse remodeling [19]. In the present study, despite similar infarct characteristics (infarct size, MVO, and IMH), improvement of GRS in younger patients was significantly less than old patients, which might partially explain the unfavorable ventricular remodeling in the younger group compared with the older group.
Cardiac remodeling involves structural, functional, and molecular changes. At the cellular and molecular levels, it is characterized by compensatory hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. In the rat myocardial infarction model, aged rats showed lower rates of rise and fall in LV pressure, less pronounced expression of atrial natriuretic factor (ANF, a marker of hypertrophy), and preserved heart function depending on remodeling, showing that aged rats well compensate for the hemodynamic overload induced by myocardial infarction [20]. Meanwhile, Gould et al [21] reported that infarct expansion and septal hypertrophy following myocardial infarction seen in the older mice, but not in the younger counterparts, could be improved with pharmacologic therapy (ACEI).
It should be noted that the proportion of females is lower in young patients in this study. Women have a lower propensity to develop spherical geometry and left ventricular dysfunction, and remodeling seems less pronounced in women. Estrogens could play a protective role in ventricular remodeling even after menopause because of persisting intramyocardial synthesis in women [22]. Even so, men and women with STEMI show a similar incidence of LV remodeling in a large cohort of 1995 STEMI patients (48% in men and 48% in women) [23]. Thus, although modest, the impact of sex on the association of age with adverse remodeling should be considered. The suggestion of greater adverse remodeling in young patients should be regarded with caution till more evidence appears from women-dominated cohorts. In terms of cardiovascular risk factors, the prevalence of stroke and diabetes in old patients was numerically higher than that of young patients. A prior echocardiography study found that the diabetes group had less adverse remodeling after STEMI compared with the non-diabetes group [24]. Thus, it brings out the hypothesis that coronary collateral circulation in diabetes [25,26,27]or angiogenesis in prior stroke [28] and hence preconditioning [29] (one of the most effective ways of protecting the heart against ischemia–reperfusion injury) might increase ischemic tolerance during the acute phase of STEMI in older patients resulting in favorable remodeling, while the occlusion of the coronary artery in young patients more likely results from rapid disease progression [2].
Age was an independent predictor of major adverse cardiac events (MACE) even after adjustment for CMR infarct characteristics [4]. Although the absolute risk and incidence for MACE after STEMI is higher in older patients with considerable age-related multimorbidity and mortality, previous myocardial infarction carries both a stronger relative risk and a greater attributable risk for poor prognosis among young people than older people. Notably, a combined population-based cohort study of Framingham Heart Study, PREVEND, and MESA showed that myocardial infarction is responsible for a greater relative risk of heart failure in younger (< 55 years) compared with older participants (hazard ratio 3.30, 95% CI 1.77 to 6.14; p < 0.001)5. Ventricular remodeling is one of the main precursors of heart failure post-myocardial infarction. In the current study, we found relatively greater LV volume enlargement in younger patients, suggesting that unfavorable cardiac remodeling post-STEMI might play some role in the relatively greater risk of heart failure. We believe this should be the focus of additional research in the future. In fact, the prognosis for younger patients with myocardial infarction is not benign. The out-of-hospital mortality from ischemic heart disease is significantly higher in very young patients than in old patients [30] In-hospital mortality among patients aged 35–49 years was 2.5% and twice as that among patients aged 60–64 years in Poland [31]. Generally, short-term outcomes post-STEMI at a ‘‘young’’ age may be good but longer prognosis is relatively poor. There is an alarming drop in long-term survival among young myocardial infarction patients after a median follow-up of 11.3 years with mortality exceeding 29% and only 19% of subjects with event-free survival at 15 years [32].
The exploratory data of subgroup analyses indicated that young patients showed a lower probability of reverse remodeling in patients without taking triple anti-remodeling drugs (β blockers, ACEI/ARB/ARNI, and MRA), or SGLT2i. Modulation of the renin–angiotensin–aldosterone and sympathetic nervous systems with ACEI/ARB, β blockers, and MRA has been shown to protect against adverse remodeling and improve survival. These drugs and combinations are recommended in guidelines as cornerstone therapies for STEMI [15] and heart failure [33]. ARNI as a replacement for ACEI in suitable patients has also shown the potential effect of reverse remodeling [34]. Additionally, two landmark trials of SGLT2i have shown a reduced risk of cardiovascular death and worsening heart failure in patients with reduced ejection fraction [35, 36]. This was also true for patients with preserved heart failure [37]. Noteworthy, ischemic heart disease accounted for more than half of the cause of heart failure in those trials [35, 36]. Although the SGLT2i trials focusing on STEMI were still ongoing (NCT03591991 and NCT05045274), we speculate the protective effects of ventricular remodeling might explain the results of subgroup analysis, which indicate no differences in reverse remodeling in patients taking SGLT2i. This is hypothesis-generating and opens the field to further research.
Limitations
We also acknowledge several limitations. First, selection bias is inherent in this retrospective study. The CMR images of the STEMI population were not consecutively included due to insufficient image quality or lack of examination. Second, the analysis was performed in a single center with a limited and male-dominated population. These exploratory results must be confirmed in a large group in the future. Third, the proportion of male patients was different between young and old groups, although multivariable adjustment by including sex as a covariate did not change the association between age and adverse or reverse remodeling. Fourth, we did not possess the images of quantitative T1 mapping as well as T2 or T2 ∗ mapping which had been provided for advanced infarct characterization including cellular and extracellular components with a potential mechanism for ventricular remodeling post-STEMI.
Conclusions
Among patients with STEMI undergoing PPCI, young patients are at a higher risk of adverse remodeling and less probably develop reverse remodeling than old patients. Equal or more attention should be paid to young patients with STEMI compared with their older counterparts.
Data Availability
Data generated or analyzed during the study are available from the corresponding author by request.
Abbreviations
- AAR:
-
Area at risk
- ACEI:
-
Angiotensin-converting enzyme inhibitor
- ARB:
-
Angiotensin receptor blocker
- ARNI:
-
Angiotensin receptor/neprilysin inhibitor
- BMI:
-
Body-mass index
- BNP:
-
Brain natriuretic peptide
- CI:
-
Confidence intervals
- CMR:
-
Cardiac magnetic resonance
- DBP:
-
Diastolic blood pressure
- ESC:
-
European Society of Cardiology
- GCS:
-
Global circumferential strain
- GLS:
-
Global longitudinal strain
- GRS:
-
Global radial strain
- HR:
-
Heart rate
- IMH:
-
Intra-myocardial hemorrhage
- IQR:
-
Inter-quartile range
- LAD:
-
Left anterior descending
- LCX:
-
Left circumflex artery
- LGE:
-
Late-enhanced images
- LV:
-
Left ventricular
- LVEDVi:
-
Left ventricular end-diastolic volume index
- LVEF:
-
Left ventricular ejection fraction
- LVESVi:
-
Left ventricular end-systolic volume index
- MRA:
-
Mineralocorticoid receptor antagonist
- MSI:
-
Myocardial salvage index
- MVO:
-
Microvascular obstruction
- OR:
-
Odds ratios
- PCI:
-
Percutaneous coronary intervention
- PCSK9i:
-
Proprotein convertase subtilisin/kexin type 9 inhibitors
- PPCI:
-
Primary percutaneous coronary intervention
- RCA:
-
Right coronary artery
- SBP:
-
Systolic blood pressure
- SD:
-
Standard deviation
- SGLT2i:
-
Sodium-glucose cotransporter 2 inhibitors
- SPSS:
-
Steady-state free precession
- STEMI:
-
ST-segment elevation myocardial infarction
- TIMI:
-
Thrombolysis in myocardial infarction
- TR/TE:
-
Repetition time/echo time
- TSE:
-
Turbo spin echo
- WHO:
-
World Health Organization
References
Ter Haar CC, Kors JA, Peters RJG et al (2020) Prevalence of ECGs exceeding thresholds for ST-segment-elevation myocardial infarction in apparently healthy individuals: the role of ethnicity. J Am Heart Assoc 9:e015477
Gulati R, Behfar A, Narula J et al (2020) Acute myocardial infarction in young individuals. Mayo Clin Proc 95:136–156
Kelly DJ, Gershlick T, Witzenbichler B et al (2011) Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. Am Heart J 162:663–670
Reinstadler SJ, Eitel C, Thieme M et al (2016) Comparison of characteristics of patients aged ≤45 years versus >45 years with ST-elevation myocardial infarction (from the AIDA STEMI CMR substudy). Am J Cardiol 117:1411–1416
Tromp J, Paniagua SMA, Lau ES et al (2021) Age dependent associations of risk factors with heart failure: pooled population based cohort study. BMJ 372:n461
Carrabba N, Parodi G, Valenti R et al (2009) Comparison of effects of primary coronary angioplasty on left ventricular remodeling and heart failure in patients <70 versus > or =70 years with acute myocardial infarction. Am J Cardiol 104:926–931
Wang J, Li L, Ma N et al (2020) Clinical investigation of acute myocardial infarction according to age subsets. Exp Ther Med 20:120
Del Turco S, Basta G, De Caterina AR et al (2019) Different inflammatory profile in young and elderly STEMI patients undergoing primary percutaneous coronary intervention (PPCI): its influence on no-reflow and mortality. Int J Cardiol 290:34–39
Khoury S, Soleman M, Margolis G et al (2020) Incidence, characteristics and outcomes in very young patients with ST segment elevation myocardial infarction. Coron Artery Dis 31:103–108
Waziri H, Jørgensen E, Kelbæk H et al (2016) Short and long-term survival after primary percutaneous coronary intervention in young patients with ST-elevation myocardial infarction. Int J Cardiol 203:697–701
Bauters C, Ennezat PV, Lamblin N et al (2010) Left ventricular remodeling and heart failure after myocardial infarction in elderly patients. Am J Cardiol 105:903–904
Innocenti F, Caldi F, Meini C et al (2010) Left ventricular remodeling in the elderly with acute anterior myocardial infarction treated with primary coronary intervention. Intern Emerg Med 5:311–319
Reindl M, Reinstadler SJ, Tiller C et al (2019) Prognosis-based definition of left ventricular remodeling after ST-elevation myocardial infarction. Eur Radiol 29:2330–2339
Bodi V, Monmeneu JV, Ortiz-Perez JT et al (2016) Prediction of reverse remodeling at cardiac MR imaging soon after first ST-segment-elevation myocardial infarction: results of a large prospective registry. Radiology 278:54–63
Ibanez B, James S, Agewall S et al (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39:119–177
World Health Organization. http://www.who.int/healthinfo/survey/ageingdefnolder/en/ Accessed 28 Aug 2017
Masci PG, Ganame J, Strata E et al (2010) Myocardial salvage by CMR correlates with LV remodeling and early ST-segment resolution in acute myocardial infarction. JACC Cardiovasc imaging 3:45–51
Topal DG, AleksovAhtarovski K, Lønborg J et al (2021) Impact of age on reperfusion success and long-term prognosis in ST-segment elevation myocardial infarction - a cardiac magnetic resonance imaging study. Int J Cardiol Heart Vasc 33:100731
Smiseth OA, Torp H, Opdahl A et al (2016) Myocardial strain imaging: how useful is it in clinical decision making? Eur Heart J 37:1196–1207
Deten A, Marx G, Briest W et al (2005) Heart function and molecular biological parameters are comparable in young adult and aged rats after chronic myocardial infarction. Cardiovasc Res 66:364–373
Gould KE, Taffet GE, Michael LH et al (2002) Heart failure and greater infarct expansion in middle-aged mice: a relevant model for postinfarction failure. Am J Physiol Heart Circ Physiol 282:H615-621
Aimo A, Panichella G, Barison A et al (2021) Sex-related differences in ventricular remodeling after myocardial infarction. Int J Cardiol 339:62–69
van der Bijl P, Abou R, Goedemans L et al (2020) Left ventricular remodelling after ST-segment elevation myocardial infarction: sex differences and prognosis. ESC Heart Fail 7:474–481
Akashi N, Tsukui T, Yamamoto K et al (2021) Comparison of clinical outcomes and left ventricular remodeling after ST-elevation myocardial infarction between patients with and without diabetes mellitus. Heart Vessels 36:1445–1456
Söğüt E, Kadı H, Karayakalı M et al (2015) The association of plasma vitamin A and E levels with coronary collateral circulation. Atherosclerosis 239:547–551
Melidonis A, Tournis S, Kouvaras G et al (1999) Comparison of coronary collateral circulation in diabetic and nondiabetic patients suffering from coronary artery disease. Clin Cardiol 22:465–471
Niccoli G, Giubilato S, Di Vito L et al (2013) Severity of coronary atherosclerosis in patients with a first acute coronary event: a diabetes paradox. Eur Heart J 34:729–741
Liu J, Wang Y, Akamatsu Y et al (2014) Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials. Prog Neurobiol 115:138–156
Lønborg J, Kelbæk H, Vejlstrup N et al (2012) Influence of pre-infarction angina, collateral flow, and pre-procedural TIMI flow on myocardial salvage index by cardiac magnetic resonance in patients with ST-segment elevation myocardial infarction. Eur Heart J Cardiovasc Imaging 13:433–443
Zhao D, Liu J, Wang M et al (2019) Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol 16:203–212
Gierlotka M, Zdrojewski T, Wojtyniak B, Poloński L et al (2015) Incidence, treatment, in-hospital mortality and one-year outcomes of acute myocardial infarction in Poland in 2009–2012–nationwide AMI-PL database. Kardiol Pol 73(3):142–158
Awad-Elkarim AA, Bagger JP, Albers CJ et al (2003) A prospective study of long term prognosis in young myocardial infarction survivors: the prognostic value of angiography and exercise testing. Heart 89:843–847
McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726
Docherty KF, Campbell RT, Brooksbank KJM et al (2021) Effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation 144:199–209
McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in Patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008
Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413–1424
Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451–1461
Funding
This study has received funding by grants from the Beijing Nova Program (Z201100006820087), the Interdisciplinary Cooperation Project of Beijing Nova Program (Z211100002121165), the National Key R&D Program of China (2020YFC2004800), the National Natural Science Foundation of China (81870322, 81900454, 81970292, 82100260), and the Natural Science Foundation of Beijing, China (7191002, 7222046).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Guarantor
The scientific guarantor of this publication is Professor Shaoping Nie.
E-mail: spnie@ccmu.edu.cn.
Conflict of interest
Dr. Shaoping Nie declares relationships with the following companies: Boston Scientific, Abbott, Jiangsu Hengrui Pharmaceuticals, China Resources Sanjiu Medical & Pharmaceuticals, East China Pharmaceuticals. The rest of the authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.
Statistics and biometry
One of the authors (Dr Wen Zheng) has significant statistical expertise.
Informed consent
Written informed consent was obtained from all patients in this study.
Ethical approval
Institutional Review Board approval was obtained. This study was approved by the institutional review board of Beijing Anzhen Hospital, Capital Medical University.
Methodology
• prospective
• observational
• performed at one institution
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Guo, R., Wang, X., Guo, Q. et al. Cardiac magnetic resonance shows increased adverse ventricular remodeling in younger patients after ST-segment elevation myocardial infarction. Eur Radiol 33, 4637–4647 (2023). https://doi.org/10.1007/s00330-023-09406-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-023-09406-5